spat has erupted in Canada over the amount of money that drug makers spend each year on R&D in the country and it comes as the government takes a closer look at coping with high prices.

Earlier this week, a government agency called the Patented Medicine Prices Review Board released a report showing that industry R&D investment was 4.4 percent of Canadian sales in 2016. This is a problem for the pharmaceutical industry, which committed 30 years ago to maintain annual R&D spending in Canada at 10 percent or more each year.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Reply to Mark Gibson Cancel reply

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.